Abstract
Background
Patients with malignant fibrous histiocytoma of bone (MFH-B) and osteosarcoma reportedly have comparable survival rates, despite the lesser chemosensitivity of patients with MFH-B compared with those with osteosarcoma.
Questions/purposes
We therefore asked (1) whether there is a difference in the initial tumor volume, histologic response, and survival between cohorts with MFH-B and osteosarcoma, and (2) whether histologic responses and survival rates differed between two groups even after matching for volume and age.
Patients and Methods
We retrospectively compared 27 patients with Stage IIB MFH-B with 389 patients with localized osteosarcoma for initial tumor volume, age, histologic response, and survival. We compared histologic response and survival between 27 patients with MFH-B and 54 patients with osteosarcoma matched for tumor volume and age.
Results
MFH-B occurred more frequently in older patients and they presented with a smaller mean tumor volume and more frequent osteolytic pattern when compared with patients with osteosarcoma. The 5-year metastasis-free survival rates of the MFH-B and osteosarcoma groups were similar: 61.2% ± 9.7% and 61.3% ± 2.5%, respectively. We observed similar proportions of good responders to chemotherapy in the two groups, and the 5-year metastasis-free survival rates were 61.2% ± 9.7% and 70.4% ± 6.2%, respectively.
Conclusions
Patients with MFH-B and osteosarcoma have similar survival rates and histologic responses to chemotherapy. Although MFH-B and osteosarcoma differ in clinical presentation, their response pattern to contemporary therapy is similar.
Level of Evidence
Level III, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
Similar content being viewed by others
References
Bacci G, Ferrari S, Bertoni F, Mercuri M, Forni C, Sottili S, Gasbarrini A, Tienghi A, Cesari M, Campanacci M. Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. J Chemother. 1997;9:293–299.
Bacci G, Picci P, Mercuri M, Bertoni F, Ferrari S. Neoadjuvant chemotherapy for high grade malignant fibrous histiocytoma of bone. Clin Orthop Relat Res. 1998;346:178–189.
Bielack SS, Schroeders A, Fuchs N, Bacci G, Bauer HC, Mapeli S, Tomeno B, Winkler K. Malignant fibrous histiocytoma of bone: a retrospective EMSOS study of 125 cases. European Musculo-Skeletal Oncology Society. Acta Orthop Scand. 1999;70:353–360.
Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848–858.
Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AH, Cannon SR, Malcolm AJ, Hogendoorn PC, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol. 1999;17:3260–3269.
Capanna R, Bertoni F, Bacchini P, Bacci G, Guerra A, Campanacci M. Malignant fibrous histiocytoma of bone: the experience at the Rizzoli Institute. Report of 90 cases. Cancer. 1984;54:177–187.
Dahlin DC, Unni KK, Matsuno T. Malignant (fibrous) histiocytoma of bone: fact or fancy? Cancer. 1977;39:1508–1516.
den Heeten GJ, Schraffordt Koops H, Kamps WA, Oosterhuis JW, Sleijfer DT, Oldhoff J. Treatment of malignant fibrous histiocytoma of bone: a plea for primary chemotherapy. Cancer. 1985;56:37–40.
deSantos LA, Edeiken B. Purely lytic osteosarcoma. Skeletal Radiol. 1982;9:1–7.
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120.
Ham SJ, Hoekstra HJ, van der Graaf WT, Kamps WA, Molenaar WM, Schraffordt Koops H. The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. J Clin Oncol. 1996;14:490–496.
Huvos AG, Heilweil M, Bretsky SS. The pathology of malignant fibrous histiocytoma of bone: a study of 130 patients. Am J Surg Pathol. 1985;9:853–871.
Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Shin DS, Jeon DG. Prognostic effect of inadvertent curettage without treatment delay in osteosarcoma. J Surg Oncol. 2009;100:484–487.
Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Shin DS, Jeon DG. Prognostic effects of doctor-associated diagnostic delays in osteosarcoma. Arch Orthop Trauma Surg. 2009;129:1421–1425.
Link TM, Haeussler MD, Poppek S, Woertler K, Blasius S, Lindner N, Rummeny EJ. Malignant fibrous histiocytoma of bone: conventional X-ray and MR imaging features. Skeletal Radiol. 1998;27:552–558.
Murphey MD, Gross TM, Rosenthal HG (1994) From the archives of the AFIP. Musculoskeletal malignant fibrous histiocytoma: radiologic-pathologic correlation. Radiographics 14:807–826; quiz 827–828.
Naka T, Fukuda T, Shinohara N, Iwamoto Y, Sugioka Y, Tsuneyoshi M. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years: a clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer. 1995;76:972–984.
Nishida J, Sim FH, Wenger DE, Unni KK. Malignant fibrous histiocytoma of bone: a clinicopathologic study of 81 patients. Cancer. 1997;79:482–493.
Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol. 1997;8:1107–1115.
Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–1230.
Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, Cacavio A, Groshen S. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(suppl):55–67.
Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res. 2000;376:200–208.
Spanier SS, Enneking WF, Enriquez P. Primary malignant fibrous histiocytoma of bone. Cancer. 1975;36:2084–2098.
Yokoyama R, Tsuneyoshi M, Enjoji M, Shinohara N, Masuda S. Prognostic factors of malignant fibrous histiocytoma of bone: a clinical and histopathologic analysis of 34 cases. Cancer. 1993;72:1902–1908.
Acknowledgments
We thank J.S. Koh, MD, M.S. Kim, MD, and Yijung Seo, RN for assistance with pathologic reviews and data collection.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors certify that they have no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might constitute a conflict of interest in connection with the submitted article.
The authors certify that their institution approved the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.
About this article
Cite this article
Jeon, DG., Song, W.S., Kong, CB. et al. MFH of Bone and Osteosarcoma Show Similar Survival and Chemosensitivity. Clin Orthop Relat Res 469, 584–590 (2011). https://doi.org/10.1007/s11999-010-1428-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11999-010-1428-z